TE-031 in urethritis

Mikio Kishi, Daisuke Yamada, Yoshitsugu Nasu, Masaya Tsugawa, Hiromi Kumon, Hiroyuki Ohmori, Katsuyoshi Kondo, Atsushi Kondo, Katsuichi Nanba

Research output: Contribution to journalArticlepeer-review


We performed a clinical study on TE-031 in urethritis and obtained the following results. 1. In 5 cases of gonococcal urethritis, clinical efficacy rates by doctor's evaluation, criteria proposed by the Trial Committee (Trial Criteria) and our own criteria were 40.0%, 80.0% and 40.0%, respectively. 2. In 13 cases of chlamydial urethritis, the three clinical efficacy rates were 92.3%, 91.7% and 77.8%, respectively. 3. In 6 cases of non-gonococcal and non-chlamydial urethritis, clinical efficacy rate by the doctor's evaluation and our criteria was 66.7% and 50.0%, respectively. 4. Bacteriologically, 4 of 5 strains of N. gonorrhoeae, and all 13 strains of C. trachomatis were eradicated. 5. Side-effects were observed in two cases, showing mild gastric discomfort. No abnormal laboratory findings were observed. Consequently, we found TE-031 less effective than other drugs such as β-lactams and SPCM for gonococcal urethritis, but clearly effective in non-gonococcal urethritis.

Original languageEnglish
Pages (from-to)842-849
Number of pages8
Publication statusPublished - Jan 1 1988

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'TE-031 in urethritis'. Together they form a unique fingerprint.

Cite this